{
    "clinical_study": {
        "@rank": "77450", 
        "brief_summary": {
            "textblock": "To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV\n      activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a\n      daily basis for 2 weeks to HIV-infected patients."
        }, 
        "brief_title": "The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive bis-POM PMEA at one of three fixed dose levels or placebo\n      daily for 2 weeks. At each dose level, nine patients receive bis-POM PMEA and three patients\n      receive placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole,\n             trimethoprim/sulfamethoxazole, or dapsone, provided a stable regimen has been\n             maintained for at least 4 weeks prior to study entry.\n\n        Patients must have:\n\n          -  HIV seropositivity.\n\n          -  CD4 count >= 100 cells/mm3.\n\n          -  p24 antigen (immune-complex dissociated) >= 50 pg/ml.\n\n          -  Life expectancy of at least 6 months.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Prior prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole,\n             trimethoprim/sulfamethoxazole, or dapsone.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Active, serious infection (other than HIV infection) requiring parenteral antibiotic\n             therapy.\n\n          -  Malignancy other than cutaneous Kaposi's sarcoma.\n\n          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive\n             heart failure, or arrhythmia.\n\n          -  Gastrointestinal malabsorption syndrome.\n\n          -  Inability to take oral medication.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any parenteral antibiotic therapy.\n\n          -  Diuretics.\n\n          -  Amphotericin B.\n\n          -  Didanosine (ddI).\n\n          -  Fluconazole.\n\n          -  Foscarnet.\n\n          -  Ganciclovir.\n\n          -  Interferon-alpha.\n\n          -  Interferon-beta.\n\n          -  Isoniazid.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Ketoconazole (topical allowed).\n\n          -  Itraconazole.\n\n          -  Rifabutin.\n\n          -  Rifampin.\n\n          -  Stavudine (d4T).\n\n          -  Zalcitabine (ddC).\n\n          -  Zidovudine (AZT).\n\n          -  Lamivudine (3TC).\n\n          -  Any investigational agents (except with sponsor approval).\n\n          -  Systemic therapy for Kaposi's sarcoma.\n\n        Patients with the following prior condition are excluded:\n\n        History of lactose intolerance.\n\n        Prior Medication:\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Any parenteral antibiotic therapy.\n\n          -  Diuretics.\n\n          -  Amphotericin B.\n\n          -  Didanosine (ddI).\n\n          -  Fluconazole.\n\n          -  Foscarnet.\n\n          -  Ganciclovir.\n\n          -  Interferon-alpha.\n\n          -  Interferon-beta.\n\n          -  Isoniazid.\n\n          -  Aminoglycoside antibiotics.\n\n          -  Ketoconazole (topical allowed).\n\n          -  Itraconazole.\n\n          -  Rifabutin.\n\n          -  Rifampin.\n\n          -  Stavudine (d4T).\n\n          -  Zalcitabine (ddC).\n\n          -  Zidovudine (AZT).\n\n          -  Lamivudine (3TC).\n\n          -  Any investigational agents (except with sponsor approval).\n\n        Excluded within 4 weeks prior to study entry:\n\n        Systemic therapy for Kaposi's sarcoma. Active substance abuse (including alcohol) as\n        determined by questionnaire or positive drug screen."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "36", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002346", 
            "org_study_id": "232B", 
            "secondary_id": "GS-93-402"
        }, 
        "intervention": {
            "intervention_name": "Adefovir dipivoxil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Adefovir", 
                "Adefovir dipivoxil"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "Adenine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Univ"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Study of Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) and Placebo in HIV-Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "11364103", 
            "citation": "James JS. GS 840 (adefovir dipivoxil): broad-spectrum antiviral trial, CD4 count under 100. AIDS Treat News. 1997 Feb 7;(No 264):4-5. No abstract available."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002346"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1995"
    }, 
    "geocoordinates": {
        "Johns Hopkins Univ": "39.29 -76.612"
    }
}